NCT05073328 (BLOC) is a clinical trial of COVID-19 required hospitalisation in COVID-19, sponsored by Mikhail Dziadzko, MD, PhD.

Who is sponsoring NCT05073328?

NCT05073328 is sponsored by Mikhail Dziadzko, MD, PhD.

What drugs are being tested in NCT05073328?

Interventions in NCT05073328: COVID-19 required hospitalisation.

What condition does NCT05073328 study?

NCT05073328 studies COVID-19, COVID Long.

Is NCT05073328 still recruiting?

NCT05073328 is currently completed. Last updated 2 October 2024.

Last reviewed 2024-10-02 · How we verify

NCT05073328: BLOC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Burden of Care of Long COVID Patients After Hospital Discharge

Completed Last updated 2 October 2024

What this trial tests

trial testing COVID-19 required hospitalisation in COVID-19 in 68,822 participants. Completed in 10 August 2022.

Timeline

1 January 2022

Primary endpoint
12 July 2022

10 August 2022

Quick facts

Lead sponsor	Mikhail Dziadzko, MD, PhD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	68,822
Start date	1 January 2022
Primary completion	12 July 2022
Estimated completion	10 August 2022
Sites	1 location across France

Drugs / interventions tested

COVID-19 required hospitalisation

Conditions studied

COVID-19 — all drugs for COVID-19 →
COVID Long — all drugs for COVID Long →

Sponsor

Mikhail Dziadzko, MD, PhD

Who can join

18 and older, any sex, with COVID-19 or COVID Long. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since March 2020, 3.5 million people have been infected with SARS-COV2 in France, and about 250 000 patients have been hospitalized and successfully discharged. In a majority of cases, the evolution of the disease is favourable, but both hospitalized or patients with a mild form of the disease may present so called "Long-COVID" syndrome - a patient-created term which describes the effects of COVID-19 that continue for weeks or months beyond the initial symptoms. There is thus an urgent need to evaluate the long-term medical resource utilisation (MRU) and health care burden incurred by patients with Long-COVID, as well as risk factors for Long-COVID. We will use the SNDS database to extract and analyze the data relevant to the project objectives. Indeed, the SNDS database is the French NHS database providing individual anonymous information of primary and secondary care linked at individual level (data from PMSI, the French DRG-based medical information system). It currently covers more than 98% of the French population. For the first time, our study will provide an estimation of MRU and associated costs of hospitalized COVID-19 patients. It will also provide an estimation of the rate of long COVID forms developed by hospitalized COVID patients, as well as detailed MRU and costs incurred by long COVID patients compared to patients with non-long COVID-19.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Health Care Resource Use and Total Mortality After Hospital Admission for Severe COVID-19 Infections During the Initial Pandemic Wave in France: Descriptive Study.
Dziadzko M, Belhassen M, Van Ganse E, Heritier F, et al · · 2024 · cited 3× · PMID 39259961 · DOI 10.2196/56398
Are Healthcare Resource Utilization Patterns for Pain Management Specific to Post-Acute COVID-19 Syndrome? A Study of Survivors from the First French Pandemic Wave.
Dziadzko M, Belhassen M, Van Ganse E, Marant-Micallef C, et al · · 2024 · cited 1× · PMID 39768603 · DOI 10.3390/jcm13247680
Distinct phenotypes of patients and healthcare resource utilization after hospitalization for COVID-19: an observational study.
Marant Micallef C, Belhassen M, Ader F, Martinez V, et al · · 2025 · PMID 39871299 · DOI 10.1186/s12913-025-12308-5

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Mikhail Dziadzko, MD, PhD trials

Trials by the same sponsor.

NCT04940208 — Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05073328 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mikhail Dziadzko, MD, PhD
Last refreshed: 2 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05073328.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing